CGRP as the target of new migraine therapies — successful translation from bench to clinic

@article{Edvinsson2018CGRPAT,
  title={CGRP as the target of new migraine therapies — successful translation from bench to clinic},
  author={Lars Edvinsson and Kristian Agmund Haanes and Karin Warfvinge and Diana N. Krause},
  journal={Nature Reviews Neurology},
  year={2018},
  volume={14},
  pages={338-350}
}
Treatment of migraine is on the cusp of a new era with the development of drugs that target the trigeminal sensory neuropeptide calcitonin gene-related peptide (CGRP) or its receptor. Several of these drugs are expected to receive approval for use in migraine headache in 2018 and 2019. CGRP-related therapies offer considerable improvements over existing drugs as they are the first to be designed specifically to act on the trigeminal pain system, they are more specific and they seem to have few… 

Blocking the CGRP Pathway for Acute and Preventative Treatment of Migraine - The Evolution of Success.

TLDR
The clinical efficacy of oral and intranasal gepants and the injectable CGRP monoclonal antibodies are described, as are recent synthetic developments which have benefited from new structural biology data.

Biological and small molecule strategies in migraine therapy with relation to the calcitonin gene‐related peptide family of peptides

TLDR
Current views on the role of the CGRP family of peptides, which are present within the trigeminovascular system but differ in expression and localization, are described and it is likely that they have different roles, which can be utilized in providing additional drug targets.

CGRP: from history to clinical application - A review

TLDR
A review of CGRP, including a brief history, focusing in C GRP mechanism, updates and future treatments is presented, especially its anatomical target sites and anti-CGRP agents.

New Trends in Migraine Pharmacology: Targeting Calcitonin Gene–Related Peptide (CGRP) With Monoclonal Antibodies

TLDR
This study aims at investigating the still poorly clear pathogenesis of migraine and the potential role of anti-CGRP mAbs in the scenario of prophylaxis of migraine.

Targeting CGRP for migraine treatment: mechanisms, antibodies, small molecules, perspectives

TLDR
The authors aim at appraising the main insights and implications of treatments targeting CGRP by reviewing pathophysiology and clinical information and suggest that Anti-CGRP MoAbs are the first migraine-specific preventive treatments representing a suitable option especially for difficult-to-treat patients.

Current status of calcitonin gene-related peptide-based therapies in migraine: a scoping review

TLDR
Evidence from animal studies elucidated the role of calcitonin gene-related peptide (CGRP) in the pathophysiology of migraine and two classes of drugs were found efficacious and safe in various clinical trials for the treatment and prevention of migraine.

CGRP-based Migraine Therapeutics: How Might They Work, Why So Safe, and What Next?

  • A. Russo
  • Biology
    ACS pharmacology & translational science
  • 2019
TLDR
Advances on several fronts are expected, including CGRP receptor structures that may help development of centrally-acting antagonists, combinatorial treatments that integrate other therapies, and development of drugs that target other neuropeptides.

Calcitonin Gene‐Related Peptide Modulators – The History and Renaissance of a New Migraine Drug Class

TLDR
Data indicated that the therapeutic site of action of the CGRP‐RAs was peripheral not central; that IV C GRP had most likely evoked migraine through an action at sites outside the blood‐brain barrier; and that migraine pain was therefore, at least in part, peripheral in origin.

CGRP inhibitors for migraine prophylaxis: a safety review

TLDR
In the last decade, clinical trials have demonstrated the efficacy of new drugs for the preventive treatment of migraine which aim to block CGRP or its receptor; increase tolerability as compared to the currently available prophylactics; and/or be more effective and safer than other treatments.
...

References

SHOWING 1-10 OF 200 REFERENCES

Calcitonin Gene-Related Peptide-Targeted Therapies for Migraine and Cluster Headache: A Review

TLDR
A growing body of clinical trials studying CGRP-targeted therapies for migraine and cluster headache is discussed, including two monoclonal antibodies in clinical trials for cluster headache prevention and several other small-molecular C GRP receptor antagonists in earlier stages of development.

CGRP receptor antagonists and antibodies against CGRP and its receptor in migraine treatment.

  • L. Edvinsson
  • Biology
    British journal of clinical pharmacology
  • 2015
TLDR
It is suggested that the antimigraine site should reside in areas not limited by the BBB such as intra- and extracranial vessels, dural mast cells and the trigeminal system, to clarify this topic and surrounding questions.

Novel migraine therapy with calcitonin gene-regulated peptide receptor antagonists

  • L. Edvinsson
  • Biology, Medicine
    Expert opinion on therapeutic targets
  • 2007
TLDR
The role of CGRP in human cranial circulation is described and the role for specific C GRP antagonism elucidated, and it is well known that triptans (5-HT1B/1D agonist) alleviate headache in part through normalisation of CgrP levels.

Possible sites of action of the new calcitonin gene-related peptide receptor antagonists

TLDR
The aim of this paper is to review recent localization studies of CGRP and its receptor components within the nervous system and to discuss whether these sites could be possible targets for the C GRP-receptor antagonists.

CGRP-receptor antagonism in migraine treatment.

TLDR
CGRP in the human cranial circulation is described to elucidate a possible role for a specific antagonist in the treatment of primary headaches and to search for small molecule CGRP antagonists, which would predictably have less cardiovascular side effects as compared to the triptans.

Therapeutic antibodies against CGRP or its receptor.

TLDR
Why CGRP is an ideal target for the prevention of migraine is reviewed and four monoclonal antibodies against either C GRP or its receptor that are in clinical development for the treatment of both episodic and chronic migraine are described.

The Trigeminovascular Pathway: Role of CGRP and CGRP Receptors in Migraine

TLDR
There is still much to learn about the role of CGRP and C GRP receptors in headache pathophysiology, the critical anatomical sites, peripheral or central, of anti‐CGRP agents, and the potential involvement of CgrP‐related peptides and receptors.

CGRP and its receptors provide new insights into migraine pathophysiology

TLDR
This Review considers the evidence pointing towards a neuronal mechanism in migraine development, highlighting the role of calcitonin gene-related peptide (CGRP), which is found in small to medium-sized neurons in the trigeminal ganglion, and examines whether other drugs, such as triptans, might exert their antimigraine effects via their actions on the neuronal circuit as opposed to the intracranial vasculature.

Calcitonin gene-related peptide receptor antagonists: new therapeutic agents for migraine.

  • I. M. Bell
  • Biology, Medicine
    Journal of medicinal chemistry
  • 2014
TLDR
The present review describes the discovery and development of these new antimigraine agents and highlights the challenges of identifying orally acting drugs that target a family B G-protein-coupled receptor.
...